^
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
sintilimab Sensitive: A1 - Approval
Innovent Biologics Press Release - 6 days (New A1)
|
sintilimab Sensitive: A1 - Approval
Innovent Biologics Press Release - 6 days - (New A1)
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Adenocarcinoma
|
No biomarker
|
Esophageal Adenocarcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Esophageal Cancer
|
PD-L1 expression
|
Esophageal Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
tislelizumab Sensitive: A1 - Approval
|
tislelizumab Sensitive: A1 - Approval
|
HER-2 negative + PD-L1 expression
|
Esophageal Adenocarcinoma
|
HER-2 negative + PD-L1 expression
|
Esophageal Adenocarcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
MSI-H/dMMR
|
Esophageal Cancer
|
MSI-H/dMMR
|
Esophageal Cancer
|
dostarlimab Sensitive: A2 - Guideline
|
dostarlimab Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
XP Sensitive: A2 - Guideline
|
XP Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Adenocarcinoma
|
No biomarker
|
Esophageal Adenocarcinoma
|
ramucirumab Sensitive: A2 - Guideline
|
ramucirumab Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
docetaxel + irinotecan Sensitive: A2 - Guideline
|
docetaxel + irinotecan Sensitive: A2 - Guideline
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
5-fluorouracil + irinotecan Sensitive: A2 - Guideline
|
5-fluorouracil + irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
irinotecan Sensitive: A2 - Guideline
|
irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
IP Sensitive: A2 - Guideline
|
IP Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
cisplatin + paclitaxel Sensitive: A2 - Guideline
|
cisplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
capecitabine + oxaliplatin Sensitive: A2 - Guideline
|
capecitabine + oxaliplatin Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Esophageal Cancer
|
NTRK3 fusion
|
Esophageal Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Esophageal Cancer
|
NTRK2 fusion
|
Esophageal Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Esophageal Cancer
|
NTRK1 fusion
|
Esophageal Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Esophageal Cancer
|
NTRK3 fusion
|
Esophageal Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Esophageal Cancer
|
NTRK2 fusion
|
Esophageal Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Esophageal Cancer
|
NTRK1 fusion
|
Esophageal Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
PD-L1 expression
|
Esophageal Adenocarcinoma
|
PD-L1 expression
|
Esophageal Adenocarcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Adenocarcinoma
|
No biomarker
|
Esophageal Adenocarcinoma
|
FP Sensitive: A2 - Guideline
|
FP Sensitive: A2 - Guideline
|
TMB-H
|
Esophageal Cancer
|
TMB-H
|
Esophageal Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline
|
paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
paclitaxel + capecitabine Sensitive: A2 - Guideline
|
paclitaxel + capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
DP Sensitive: A2 - Guideline
|
DP Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Adenocarcinoma
|
No biomarker
|
Esophageal Adenocarcinoma
|
FLOT Sensitive: A2 - Guideline
|
FLOT Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
oxaliplatin Sensitive: A2 - Guideline
|
oxaliplatin Sensitive: A2 - Guideline
|
HER-2 negative + PD-L1 expression
|
Esophageal Cancer
|
HER-2 negative + PD-L1 expression
|
Esophageal Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
HER-2 negative
|
Esophageal Cancer
|
HER-2 negative
|
Esophageal Cancer
|
XP Sensitive: A2 - Guideline
|
XP Sensitive: A2 - Guideline
|
HER-2 negative
|
Esophageal Cancer
|
HER-2 negative
|
Esophageal Cancer
|
FP Sensitive: A2 - Guideline
|
FP Sensitive: A2 - Guideline
|
HER-2 negative
|
Esophageal Cancer
|
HER-2 negative
|
Esophageal Cancer
|
capecitabine + oxaliplatin Sensitive: A2 - Guideline
|
capecitabine + oxaliplatin Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
DOF Sensitive: A2 - Guideline
|
DOF Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
carboplatin + 5-fluorouracil + docetaxel Sensitive: A2 - Guideline
|
carboplatin + 5-fluorouracil + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
TPF Sensitive: A2 - Guideline
|
TPF Sensitive: A2 - Guideline
|
No biomarker
|
Esophageal Adenocarcinoma
|
No biomarker
|
Esophageal Adenocarcinoma
|
FOLFOX Sensitive: A2 - Guideline
|
FOLFOX Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
HER-2 overexpression
|
Esophageal Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
HER-2 overexpression
|
Esophageal Cancer
|
HER-2 overexpression
|
Esophageal Cancer
|
pembrolizumab + trastuzumab Sensitive: A2 - Guideline
|
pembrolizumab + trastuzumab Sensitive: A2 - Guideline
|
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
|
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
|
erlotinib Sensitive: B - Late Trials
|
erlotinib Sensitive: B - Late Trials
|
PD-L1 expression
|
Esophageal Adenocarcinoma
|
PD-L1 expression
|
Esophageal Adenocarcinoma
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
tislelizumab Sensitive: B - Late Trials
|
tislelizumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
sintilimab Sensitive: B - Late Trials
|
sintilimab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Esophageal Adenocarcinoma
|
PD-L1 overexpression
|
Esophageal Adenocarcinoma
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
PD-L1 underexpression
|
Esophageal Adenocarcinoma
|
PD-L1 underexpression
|
Esophageal Adenocarcinoma
|
Immunotherapy Resistant: B - Late Trials
|
Immunotherapy Resistant: B - Late Trials
|
NTRK3 fusion
|
Esophageal Squamous Cell Carcinoma
|
NTRK3 fusion
|
Esophageal Squamous Cell Carcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
Esophageal Squamous Cell Carcinoma
|
NTRK2 fusion
|
Esophageal Squamous Cell Carcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK1 fusion
|
Esophageal Squamous Cell Carcinoma
|
NTRK1 fusion
|
Esophageal Squamous Cell Carcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
EGFR mutation
|
Esophageal Squamous Cell Carcinoma
|
EGFR mutation
|
Esophageal Squamous Cell Carcinoma
|
afatinib Sensitive: C1 - Off-label
|
afatinib Sensitive: C1 - Off-label
|
HER-2 overexpression
|
Esophageal Cancer
|
HER-2 overexpression
|
Esophageal Cancer
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
trastuzumab + pertuzumab Sensitive: C1 - Off-label
|
trastuzumab + pertuzumab Sensitive: C1 - Off-label
|
HER-2 positive
|
Esophageal Squamous Cell Carcinoma
|
HER-2 positive
|
Esophageal Squamous Cell Carcinoma
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Esophageal Adenocarcinoma
|
MSI-H/dMMR
|
Esophageal Adenocarcinoma
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
camrelizumab Sensitive: C2 – Inclusion Criteria
|
camrelizumab Sensitive: C2 – Inclusion Criteria
|
EGFR amplification
|
Esophageal Squamous Cell Carcinoma
|
EGFR amplification
|
Esophageal Squamous Cell Carcinoma
|
afatinib Sensitive: C2 – Inclusion Criteria
|
afatinib Sensitive: C2 – Inclusion Criteria
|
MYC amplification
|
Esophageal Cancer
|
MYC amplification
|
Esophageal Cancer
|
ibrutinib Sensitive: C2 – Inclusion Criteria
|
ibrutinib Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Esophageal Cancer
|
HER-2 amplification
|
Esophageal Cancer
|
ibrutinib Sensitive: C2 – Inclusion Criteria
|
ibrutinib Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Esophageal Cancer
|
HER-2 amplification
|
Esophageal Cancer
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|
CLDN18.2 expression
|
Esophageal Adenocarcinoma
|
CLDN18.2 expression
|
Esophageal Adenocarcinoma
|
IMAB362 Sensitive: C2 – Inclusion Criteria
|
IMAB362 Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Esophageal Adenocarcinoma
|
HER-2 amplification
|
Esophageal Adenocarcinoma
|
trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
Esophageal Cancer
|
PD-L1 expression
|
Esophageal Cancer
|
atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria
|
atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria
|
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
|
EGFR overexpression
|
Esophageal Squamous Cell Carcinoma
|
Z650 Sensitive: C2 – Inclusion Criteria
|
Z650 Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
toripalimab Sensitive: C2 – Inclusion Criteria
|
toripalimab Sensitive: C2 – Inclusion Criteria
|
NRG1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
NRG1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
AV-203 Sensitive: C3 – Early Trials
|
AV-203 Sensitive: C3 – Early Trials
|
NDRG1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
NDRG1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
cisplatin + 5-fluorouracil Resistant: C3 – Early Trials
|
cisplatin + 5-fluorouracil Resistant: C3 – Early Trials
|
SGK1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
SGK1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
cisplatin + 5-fluorouracil Resistant: C3 – Early Trials
|
cisplatin + 5-fluorouracil Resistant: C3 – Early Trials
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
paclitaxel Resistant: C3 – Early Trials
|
paclitaxel Resistant: C3 – Early Trials
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
carboplatin Resistant: C3 – Early Trials
|
carboplatin Resistant: C3 – Early Trials
|
AFAP1-AS1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
AFAP1-AS1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
FP Resistant: C3 – Early Trials
|
FP Resistant: C3 – Early Trials
|
ARID1A mutation
|
Esophageal Adenocarcinoma
|
ARID1A mutation
|
Esophageal Adenocarcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
TLR signature
|
Esophageal Squamous Cell Carcinoma
|
TLR signature
|
Esophageal Squamous Cell Carcinoma
|
tislelizumab Sensitive: C3 – Early Trials
|
tislelizumab Sensitive: C3 – Early Trials
|
NDRG1-H
|
Esophageal Squamous Cell Carcinoma
|
NDRG1-H
|
Esophageal Squamous Cell Carcinoma
|
cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials
|
cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials
|
DKK1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
DKK1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
pembrolizumab + DKN-01 Sensitive: C3 – Early Trials
|
pembrolizumab + DKN-01 Sensitive: C3 – Early Trials
|
DKK1 overexpression
|
Esophageal Adenocarcinoma
|
DKK1 overexpression
|
Esophageal Adenocarcinoma
|
pembrolizumab + DKN-01 Sensitive: C3 – Early Trials
|
pembrolizumab + DKN-01 Sensitive: C3 – Early Trials
|
DKK1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
DKK1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
DKN-01 Sensitive: C3 – Early Trials
|
DKN-01 Sensitive: C3 – Early Trials
|
DKK1 overexpression
|
Esophageal Adenocarcinoma
|
DKK1 overexpression
|
Esophageal Adenocarcinoma
|
DKN-01 Sensitive: C3 – Early Trials
|
DKN-01 Sensitive: C3 – Early Trials
|
NFKB1 expression
|
Esophageal Squamous Cell Carcinoma
|
NFKB1 expression
|
Esophageal Squamous Cell Carcinoma
|
rivoceranib Sensitive: C3 – Early Trials
|
rivoceranib Sensitive: C3 – Early Trials
|
KDR expression
|
Esophageal Squamous Cell Carcinoma
|
KDR expression
|
Esophageal Squamous Cell Carcinoma
|
rivoceranib Sensitive: C3 – Early Trials
|
rivoceranib Sensitive: C3 – Early Trials
|
PD-L1 overexpression + CCL5 overexpression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 overexpression + CCL5 overexpression
|
Esophageal Squamous Cell Carcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
